ERBB2 and type 1 diabetes mellitus: Lapatinib is a dual inhibitor of EGFR and ErbB2 receptor tyrosine kinases, by which high glucose-induced apoptosis and vascular dysfunction were refined via resistance to signaling changes influenced by diabetes in the experimental T1D models (34, 51).